JP2021100944A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021100944A5 JP2021100944A5 JP2021038385A JP2021038385A JP2021100944A5 JP 2021100944 A5 JP2021100944 A5 JP 2021100944A5 JP 2021038385 A JP2021038385 A JP 2021038385A JP 2021038385 A JP2021038385 A JP 2021038385A JP 2021100944 A5 JP2021100944 A5 JP 2021100944A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antigen
- hpv
- vaccine
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 41
- 102000036639 antigens Human genes 0.000 claims 41
- 108091007433 antigens Proteins 0.000 claims 41
- 229960005486 vaccine Drugs 0.000 claims 34
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 201000011510 cancer Diseases 0.000 claims 24
- 241000701806 Human papillomavirus Species 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 238000011282 treatment Methods 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 12
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 12
- 241000711549 Hepacivirus C Species 0.000 claims 12
- 101710142969 Somatoliberin Proteins 0.000 claims 12
- 230000002265 prevention Effects 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 9
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 9
- 241000700721 Hepatitis B virus Species 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 6
- 102000036673 PRAME Human genes 0.000 claims 6
- 108060006580 PRAME Proteins 0.000 claims 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 6
- 239000013612 plasmid Substances 0.000 claims 5
- 241000701828 Human papillomavirus type 11 Species 0.000 claims 4
- 102000003425 Tyrosinase Human genes 0.000 claims 4
- 108060008724 Tyrosinase Proteins 0.000 claims 4
- 238000011321 prophylaxis Methods 0.000 claims 4
- 101710132601 Capsid protein Proteins 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 3
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 3
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 3
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 3
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 3
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 206010038707 Respiratory papilloma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 208000001307 recurrent respiratory papillomatosis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799952P | 2013-03-15 | 2013-03-15 | |
| US61/799,952 | 2013-03-15 | ||
| JP2019026468A JP7256024B2 (ja) | 2013-03-15 | 2019-02-18 | ガンワクチン及びそれを用いた治療方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019026468A Division JP7256024B2 (ja) | 2013-03-15 | 2019-02-18 | ガンワクチン及びそれを用いた治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021100944A JP2021100944A (ja) | 2021-07-08 |
| JP2021100944A5 true JP2021100944A5 (enExample) | 2021-08-26 |
Family
ID=51538388
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503109A Active JP6769865B2 (ja) | 2013-03-15 | 2014-03-14 | ガンワクチン及びそれを用いた治療方法 |
| JP2019026468A Active JP7256024B2 (ja) | 2013-03-15 | 2019-02-18 | ガンワクチン及びそれを用いた治療方法 |
| JP2021038385A Pending JP2021100944A (ja) | 2013-03-15 | 2021-03-10 | ガンワクチン及びそれを用いた治療方法 |
| JP2022184046A Pending JP2023021127A (ja) | 2013-03-15 | 2022-11-17 | ガンワクチン及びそれを用いた治療方法 |
| JP2025102558A Pending JP2025129169A (ja) | 2013-03-15 | 2025-06-18 | ガンワクチン及びそれを用いた治療方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503109A Active JP6769865B2 (ja) | 2013-03-15 | 2014-03-14 | ガンワクチン及びそれを用いた治療方法 |
| JP2019026468A Active JP7256024B2 (ja) | 2013-03-15 | 2019-02-18 | ガンワクチン及びそれを用いた治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022184046A Pending JP2023021127A (ja) | 2013-03-15 | 2022-11-17 | ガンワクチン及びそれを用いた治療方法 |
| JP2025102558A Pending JP2025129169A (ja) | 2013-03-15 | 2025-06-18 | ガンワクチン及びそれを用いた治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11419925B2 (enExample) |
| EP (2) | EP3607974A1 (enExample) |
| JP (5) | JP6769865B2 (enExample) |
| KR (4) | KR20250162628A (enExample) |
| CN (2) | CN105025932B (enExample) |
| AU (5) | AU2014228405B2 (enExample) |
| BR (1) | BR112015022367B1 (enExample) |
| CA (1) | CA2898126A1 (enExample) |
| EA (2) | EA201992251A1 (enExample) |
| MX (2) | MX369709B (enExample) |
| WO (1) | WO2014144885A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| EP2010209B1 (en) | 2006-04-10 | 2016-06-15 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| EP3520810A3 (en) | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
| WO2014093886A1 (en) * | 2012-12-13 | 2014-06-19 | The Trustees Of The University Of Pennsylvania | Wt1 vaccine |
| PL2945647T3 (pl) | 2013-01-15 | 2021-03-08 | Memorial Sloan Kettering Cancer Center | Immunogenne peptydy wt-1 i sposoby ich zastosowania |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| BR112015022367B1 (pt) * | 2013-03-15 | 2021-06-22 | The Trustees Of The University Of Pennsylvania | Vacina, molécula de ácido nucleico, e, molécula de aminoácido |
| CA2935375C (en) * | 2014-01-06 | 2023-08-08 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| CN114081946A (zh) | 2014-03-12 | 2022-02-25 | 耶达研究与开发有限公司 | 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤 |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| AU2015279738A1 (en) | 2014-06-25 | 2016-12-22 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
| CN107427567A (zh) | 2015-01-29 | 2017-12-01 | 宾夕法尼亚大学理事会 | 检查点抑制剂和疫苗组合物及其用于免疫疗法的用途 |
| WO2016168361A1 (en) * | 2015-04-14 | 2016-10-20 | Polynoma, Llc | Polyvalent vaccines and combination therapy for the treatment of melanoma |
| WO2017060360A1 (en) * | 2015-10-06 | 2017-04-13 | Invectys | Polyepitope constructs for use in immunotherapy |
| EP3371210B1 (en) * | 2015-11-04 | 2022-05-25 | Taipei Veterans General Hospital | Combination therapy for malignant diseases |
| RS63561B1 (sr) * | 2015-11-20 | 2022-10-31 | Memorial Sloan Kettering Cancer Center | Kompozicija za lečenje raka |
| TWI654302B (zh) | 2016-01-19 | 2019-03-21 | 輝瑞股份有限公司 | 癌症疫苗 |
| EP3405203A4 (en) * | 2016-01-22 | 2019-07-24 | X4 Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| WO2017136758A1 (en) | 2016-02-05 | 2017-08-10 | Inovio Pharmaceuticals, Inc. | Cancer vaccines and methods of treatment using the same |
| US10842743B2 (en) | 2016-04-08 | 2020-11-24 | The Regents Of The University Of California | Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents |
| LT3463436T (lt) | 2016-06-02 | 2024-01-25 | Ultimovacs Asa | Vakcina derinyje su imuninės patikros taško slopikliu, skirta vėžiui gydyti |
| EP3516390A1 (en) | 2016-09-23 | 2019-07-31 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Manipulation of immune activity by modulation of expression |
| JP7781511B2 (ja) | 2016-09-30 | 2025-12-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｔｅｒｔ免疫原性組成物及びそれを用いた治療方法 |
| US11666646B2 (en) | 2016-12-26 | 2023-06-06 | National University Corporation Kobe University | Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor |
| CA3052803A1 (en) | 2017-02-07 | 2018-08-16 | Nantcell, Inc. | Maximizing t-cell memory and compositions and methods therefor |
| MY192920A (en) * | 2017-03-15 | 2022-09-15 | Cancer Res Malaysia | Immunogenic peptide composition |
| WO2019118760A1 (en) * | 2017-12-13 | 2019-06-20 | Inovio Pharmaceuticals, Inc. | Cancer vaccines targeting mesothelin and uses thereof |
| PL3737397T3 (pl) * | 2017-12-13 | 2023-03-27 | Inovio Pharmaceuticals, Inc. | Szczepionki przeciwnowotworowe ukierunkowane do prame i ich zastosowania |
| FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
| TWI816603B (zh) | 2018-04-23 | 2023-09-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
| US11564980B2 (en) * | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
| JP2021525549A (ja) * | 2018-05-25 | 2021-09-27 | ザ ウィスター インスティテュート | 腫瘍特異的ネオ抗原およびその使用方法 |
| WO2020020444A1 (en) * | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| WO2021051065A1 (en) * | 2019-09-12 | 2021-03-18 | Inovio Pharmaceuticals, Inc. | Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same |
| WO2021127617A1 (en) * | 2019-12-19 | 2021-06-24 | The Wistar Institute Of Anatomy And Biology | Vaccines against african swine fever virus, and methods of using same |
| EP4117662A4 (en) | 2020-03-10 | 2024-04-03 | X4 Pharmaceuticals, Inc. | METHODS OF TREATING NEUTROPENIA |
| KR20230011335A (ko) | 2020-05-14 | 2023-01-20 | 이노비오 파마수티컬즈, 인크. | 재발성 호흡기 유두종증에 대한 백신 및 이의 사용 방법 |
| CN111647066B (zh) * | 2020-07-01 | 2020-12-18 | 维肽瀛(上海)生物技术有限公司 | Wt1多肽肿瘤抑制剂 |
| CN114113611B (zh) * | 2021-12-13 | 2023-07-14 | 郑州大学 | 一种用于肝癌诊断的生物标志物及检测试剂盒 |
| WO2023141534A1 (en) * | 2022-01-19 | 2023-07-27 | Northwestern University | Agents that target telomerase reverse transcriptase (tert) for treating cancer and sensitizing cancer cells to genotoxic therapy |
| AU2023231218A1 (en) * | 2022-03-08 | 2024-07-25 | Immunitybio, Inc. | Intratumorally injected yeast vaccine |
| CN115845039A (zh) * | 2022-07-01 | 2023-03-28 | 可蓝赛生物医药(上海)有限公司 | 一种广谱多肽肿瘤疫苗组成 |
| EP4601687A1 (en) * | 2022-10-13 | 2025-08-20 | Inovio Pharmaceuticals, Inc. | Vaccines for recurrent respiratory papillomatosis and methods of using the same |
| CN118141903B (zh) * | 2024-03-11 | 2025-09-23 | 上海申锐联生物医药有限公司 | 一种治疗犬黑色素瘤的环状rna疫苗 |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
| US4790987A (en) | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
| US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| AU625584B2 (en) | 1989-03-08 | 1992-07-16 | Health Research Inc. | Recombinant poxvirus host selection system |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| JP3004049B2 (ja) | 1989-03-31 | 2000-01-31 | ワシントン ユニバーシティー | 病原性のないｐｈｏＰ型微生物を含有するワクチン |
| EP0431668B1 (en) | 1989-12-04 | 1995-02-15 | Akzo Nobel N.V. | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof |
| US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
| AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
| US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
| US5925729A (en) * | 1991-05-23 | 1999-07-20 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
| US6034298A (en) | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
| US5955088A (en) | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| WO1994016737A1 (en) | 1993-01-26 | 1994-08-04 | Weiner David B | Compositions and methods for delivery of genetic material |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5864027A (en) | 1993-06-07 | 1999-01-26 | Genentech, Inc. | HIV envelope polypeptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US6156319A (en) | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
| NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
| US5843648A (en) * | 1995-01-10 | 1998-12-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5650309A (en) | 1995-05-16 | 1997-07-22 | The Regents Of The University Of California | Viral vectors |
| US5698202A (en) | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
| US7501501B2 (en) * | 1995-09-26 | 2009-03-10 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | MHC-Class II restricted melanoma antigens and their use in therapeutic methods |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6946133B1 (en) * | 1996-03-20 | 2005-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
| CA2269074A1 (en) | 1996-10-23 | 1998-04-30 | The Trustees Of The University Of Pennsylvania | Immunotherapy and improved vaccines |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| AU733628B2 (en) | 1997-04-03 | 2001-05-17 | Electrofect As | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| JP2002507985A (ja) | 1997-06-30 | 2002-03-12 | ローヌ−プーラン・ロレ・エス・アー | 横紋筋に核酸を導入する改良法およびその組合せ |
| US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| CA2337652C (en) | 1998-07-13 | 2013-03-26 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US6589529B1 (en) | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
| CN1348332A (zh) * | 1999-03-03 | 2002-05-08 | 宾夕法尼亚大学理事会 | 疫苗和基因治疗组合物以及其制备和使用方法 |
| AU5741001A (en) * | 2000-04-28 | 2001-11-12 | Ctl Immunotherapies Corp | Epitope synchronization in antigen presenting cells |
| US20030215425A1 (en) | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| WO2002068653A2 (en) * | 2001-02-26 | 2002-09-06 | Imclone Systems Incorporated | Tri-hybrid melanoma antigen |
| US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| EP1260229A3 (en) | 2001-05-18 | 2002-12-11 | Sumitomo Pharmaceuticals Company, Limited | Anti-autoimmune composition comprising inhibitors of growth hormone-releasing factor activity |
| JP4273293B2 (ja) | 2001-05-18 | 2009-06-03 | 大日本住友製薬株式会社 | Ｇｒｆ作用の阻害による新規抗自己免疫疾患剤、及びそのスクリーニング方法 |
| EP1270732A1 (en) | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| DE60238864D1 (de) * | 2001-11-07 | 2011-02-17 | Mankind Corp | Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| AU2003249357A1 (en) * | 2002-06-27 | 2004-01-19 | Geron Corporation | Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| WO2004016643A2 (en) * | 2002-08-16 | 2004-02-26 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| PT1553966E (pt) * | 2002-10-03 | 2012-10-22 | Wyeth Corp | Péptidos de fusão que compreendem os polipéptidos e7 e e6 do vírus do papiloma humano e as composições imunogénicas dos mesmos |
| TWI290174B (en) | 2002-11-04 | 2007-11-21 | Advisys Inc | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| WO2004048938A2 (en) * | 2002-11-26 | 2004-06-10 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| MXPA05010255A (es) * | 2003-03-24 | 2005-12-14 | Scripps Research Inst | Vacunas de adn contra crecimiento tumoral y metodos de uso de las mismas. |
| DK1628749T3 (da) | 2003-05-30 | 2019-09-16 | Vgxi Inc | Anordninger og fremgangsmåder til biomateriel produktion |
| JP2007511534A (ja) | 2003-11-13 | 2007-05-10 | スローン−ケッタリング インスティトゥート フォー カンサー リサーチ | 抗腫瘍免疫の相乗的誘導のための組成物および方法 |
| EP3263032B1 (en) * | 2003-12-09 | 2024-01-24 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
| GB0401876D0 (en) | 2004-01-28 | 2004-03-03 | Vereniging Het Nl Kanker I | New use for cancer antigen |
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| AU2013203229C1 (en) * | 2006-07-28 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| KR101999376B1 (ko) | 2006-07-28 | 2019-07-11 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 백신 및 이의 사용 방법 |
| AU2007342338A1 (en) | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies |
| US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US8871211B2 (en) * | 2006-09-28 | 2014-10-28 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| CN101522706B (zh) * | 2006-10-12 | 2013-09-04 | P.安杰莱蒂分子生物学研究所 | 端粒酶逆转录酶融合蛋白、编码它的核苷酸以及其用途 |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| CA2685069C (en) | 2007-05-23 | 2019-01-15 | Vgx Pharmaceuticals, Inc. | Compositions comprising high concentration of biologically active molecules and processes for preparing the same |
| KR101609233B1 (ko) | 2008-10-29 | 2016-04-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개량된 ｈｃｖ 백신 및 이를 이용하는 방법 |
| US8961994B2 (en) | 2008-11-17 | 2015-02-24 | Vgx Pharmaceuticals, Llc | DNA constructs eliciting immune response against flavivirus and effective adjuvants |
| WO2010068680A1 (en) | 2008-12-10 | 2010-06-17 | Mount Sinai School Of Medicine Of New York University | Thelper cell type 17 lineage-specific adjuvants, compositions and methods |
| CA2653478A1 (en) | 2009-01-23 | 2010-07-23 | Gregg Martin | Automated wash system for industrial vehicles |
| CA2764760C (en) * | 2009-06-09 | 2019-11-26 | Vaxon Biotech | Identification, optimization and use of shared hla-b*0702 epitopes for immunotherapy |
| CN102574899A (zh) | 2009-08-14 | 2012-07-11 | 阿勒根公司 | 使用胰高血糖素样激素再靶向内肽酶治疗癌症的方法 |
| WO2011073901A1 (en) * | 2009-12-14 | 2011-06-23 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| CN102781952B (zh) | 2010-02-08 | 2015-09-02 | 宾夕法尼亚大学托管会 | 编码rantes的核酸分子、包含其的组合物以及其使用方法 |
| JP5975983B2 (ja) | 2010-04-16 | 2016-08-23 | ベリカム ファーマシューティカルズ， インコーポレイテッド | 固形腫瘍を処置するための方法 |
| ES2664872T3 (es) | 2010-06-18 | 2018-04-23 | Taiho Pharmaceutical Co., Ltd | Moduladores PRPK-TPRKB y sus usos |
| MX346784B (es) | 2010-11-12 | 2017-03-31 | Inovio Pharmaceuticals Inc | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. |
| US20140236070A1 (en) * | 2011-07-29 | 2014-08-21 | Kate Broderick | Linear expression cassettes and uses thereof |
| SG11201406592QA (en) * | 2012-05-04 | 2014-11-27 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| CA2894966C (en) | 2012-12-14 | 2021-03-30 | Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz | Novel mhc-independent tumor-associated antigens |
| BR112015022367B1 (pt) * | 2013-03-15 | 2021-06-22 | The Trustees Of The University Of Pennsylvania | Vacina, molécula de ácido nucleico, e, molécula de aminoácido |
-
2014
- 2014-03-14 BR BR112015022367-2A patent/BR112015022367B1/pt active IP Right Grant
- 2014-03-14 AU AU2014228405A patent/AU2014228405B2/en active Active
- 2014-03-14 EP EP19187568.1A patent/EP3607974A1/en active Pending
- 2014-03-14 KR KR1020257036389A patent/KR20250162628A/ko active Pending
- 2014-03-14 US US14/775,047 patent/US11419925B2/en active Active
- 2014-03-14 EA EA201992251A patent/EA201992251A1/ru unknown
- 2014-03-14 WO PCT/US2014/029479 patent/WO2014144885A2/en not_active Ceased
- 2014-03-14 JP JP2016503109A patent/JP6769865B2/ja active Active
- 2014-03-14 CN CN201480011372.2A patent/CN105025932B/zh active Active
- 2014-03-14 EP EP14764579.0A patent/EP2968607B1/en active Active
- 2014-03-14 CN CN202111612889.5A patent/CN114225019A/zh active Pending
- 2014-03-14 MX MX2015011486A patent/MX369709B/es active IP Right Grant
- 2014-03-14 KR KR1020237014283A patent/KR20230062674A/ko not_active Ceased
- 2014-03-14 KR KR1020157024377A patent/KR20150130284A/ko not_active Ceased
- 2014-03-14 KR KR1020217031786A patent/KR20210123426A/ko not_active Ceased
- 2014-03-14 CA CA2898126A patent/CA2898126A1/en active Pending
- 2014-03-14 EA EA201591674A patent/EA034110B1/ru not_active IP Right Cessation
-
2015
- 2015-09-02 MX MX2019013756A patent/MX2019013756A/es unknown
-
2017
- 2017-08-10 AU AU2017213514A patent/AU2017213514B2/en active Active
-
2019
- 2019-02-18 JP JP2019026468A patent/JP7256024B2/ja active Active
- 2019-11-08 AU AU2019261784A patent/AU2019261784A1/en not_active Abandoned
-
2021
- 2021-03-10 JP JP2021038385A patent/JP2021100944A/ja active Pending
-
2022
- 2022-01-04 AU AU2022200016A patent/AU2022200016B2/en active Active
- 2022-07-20 US US17/813,762 patent/US20230012022A1/en active Pending
- 2022-11-17 JP JP2022184046A patent/JP2023021127A/ja active Pending
-
2024
- 2024-05-13 AU AU2024203144A patent/AU2024203144A1/en active Pending
-
2025
- 2025-06-18 JP JP2025102558A patent/JP2025129169A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021100944A5 (enExample) | ||
| JP2016516723A5 (enExample) | ||
| Wu et al. | Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus | |
| Su et al. | The effects of IL-6 and TNF-α as molecular adjuvants on immune responses to FMDV and maturation of dendritic cells by DNA vaccination | |
| CN104640565B (zh) | 乙型肝炎病毒核心蛋白和表面抗原蛋白以及包含其的疫苗 | |
| JP2019526580A5 (enExample) | ||
| Pishraft-Sabet et al. | Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96 | |
| Yu et al. | A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice | |
| Lee et al. | Recommendations for the use of Japanese encephalitis vaccines | |
| Moingeon et al. | Therapeutic vaccines against infectious diseases | |
| US8691234B2 (en) | Vaccine formulation potentiated by the combination of DNA and an antigen | |
| Zhou et al. | Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine | |
| Saade et al. | Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes | |
| US10160979B2 (en) | Pharmaceutical composition for treatment and/or prevention of hepatitis C | |
| Shi et al. | Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes | |
| Boukhebza et al. | Comparative analysis of immunization schedules using a novel adenovirus-based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models | |
| WO2015113187A1 (zh) | 一种以流感病毒为载体的hcv嵌合疫苗及其制备方法 | |
| Karayiannis et al. | Hepatitis vaccines | |
| CN115925824A (zh) | SARS-CoV-2编码蛋白来源的T细胞表位多肽NVFAFPFTI及其应用 | |
| Nam et al. | Modulation of immune response induced by co-administration of DNA vaccine encoding HBV surface antigen and HCV envelope antigen in BALB/c mice | |
| Babu et al. | Cancer vaccine: a review | |
| Liu | DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress. Cancers 2022, 14, 5874 | |
| CN109422813A (zh) | HBs-α317ScFv重组蛋白、其编码序列、表达载体及应用 | |
| CN107648601B (zh) | 一种丙型肝炎病毒三价亚单位疫苗的制备及应用 | |
| Han et al. | DNA vaccines against infectious diseases and cancer |